SO010/#1243 Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer -the sentirec-endo study

• DOI: 10.1136/ijgc-2023-igcs.24
• Publication Date: 2023-11-08T07:00:51Z
• Authors: Sarah Bjørnholt; Sara Sponholtz; Ole Mogensen; Kirsten Bouchelouche; Erik Parner; Gudrun Neumann; Kirsten Jochumsen; Bushra Hamid; Morten Davidsen; Signe Bjørn; Katja Dahl; Pernille Jensen

<h3>Introduction</h3> Surgical staging of endometrial cancer (EC) serves to allocate women with lymph node metastases adjuvant treatment. Sentinel (SLN) mapping can accurately detect in EC low- or intermediate-risk (LR IR) metastases. We aim investigate risks and benefits a national protocolled adoption SLN LR IR EC, real-life clinical setting. <h3>Methods</h3> A multicenter prospective study SLN-mapping from March 2017-February 2022. Postoperative complications were classified according Clavien-Dindo. Lymphoedema was evaluated by validated patient-reported outcome measures at baseline three months postoperatively. <h3>Results</h3> 627 included the analyses, 458 LR- 169 EC. The detection rate 94.3% (591/627). overall incidence 9.3% (58/627), 4.4% (20/458) 22.5% (38/169) group. Only 0.3% (2/627) experienced an intraoperative complication associated procedure. postoperative 8% (50/627). mean difference score lymphoedema below threshold for importance 4.3/100 (95%CI 2.6–5.9). leg swelling heaviness low, 5.2% 6.1%, respectively. <h3>Conclusion/Implications</h3> is safe procedure IR, carrying very low risk early lymphoedema, perioperative- complications. change practice contributed improved treatment allocation both groups thus supports further international implementation.